Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Biotech Sector's Technological Advancements Winning Major Battles in the War on Cancer

LOS ANGELES, Jan. 17, 2020 /PRNewswire/ -- USA News Group – In the war against cancer, it appears that all hands are on deck, with contributions coming from across the biotech sector. As the 2020s begin, new approvals and promising data are encouraging the market to pay more attention to the developers of new treatments, including Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), GlaxoSmithKline plc (NYSE:GSK), Aethlon Medical, Inc. (NASDAQ:AEMD), Clovis Oncology, Inc. (NASDAQ:CLVS), and Merck & Co., Inc. (NYSE:MRK). Market researchers see big things to come from investment into the oncological war, with recent forecasts such as: the cancer gene therapy market surpassing $3.2 billion by 2026; the global breast cancer drug market offering a $40 billion opportunity; the noninvasive cancer diagnostics market hitting $195 billion by 2025; and the immunotherapy market estimated to reach $115 billion by 2023. One thriving example an important enhancement therapy is pelareorep from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC)—an immuno-oncolytic virus (OV) being combined some of the world's top selling anti-cancer drugs, including Keytruda ($7.2B in 2018 sales for Merck), Opdivo ($6.7B in 2018 sales for Bristol-Myers Squibb), Tecentriq ($766M in 2018 sales for Roche) and Bavencio ($75.5M in 2018 sales for Pfizer/Merck). Recently Reuters published an analysis that revealed a record 89 therapies are currently undergoing human trials involving the pairing of treatments with antibodies with toxic agents to fight cancer—which Reuters calls "guided-missile" cancer drugs.

First found on: And then on: 1 other references